Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results

Gross margin for the fourth quarter of 2010 was 62% compared with 50% for the fourth quarter of 2009, reflecting improved margins and changes in the mix of products sold in the company’s genetic analysis segment, as well as improved margins associated with increased test volumes within the diagnostics segment at the company’s wholly-owned molecular diagnostics laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM).

Source: Sequenom